Jon Edelson, MD

Jon Edelson, MD, is the Chairman, CEO, and President of Eirion Therapeutics

Articles

What’s Next for ET-02? CEO of Eirion, Jon Edelson, MD, Shares Phase 2 Plans

Marie Bosslett, Assistant Editor;Jon Edelson, MD

January 14th 2025

“As good as we saw results in 1 month, we think we'll see even more remarkable results over the 6 months of treatment,” Edelson said in an interview with Dermatology Times.

The Unprecedented Phase 1 Results of ET-02 for the Treatment of Androgenic Alopecia

Marie Bosslett, Assistant Editor;Jon Edelson, MD

January 14th 2025

Jon Edelson, MD, CEO of Eirion, confirms that topical ET-02 is a completely new approach to treating this type of hair loss.

Latest Updated Articles

Published: September 19th 2024 | Updated: September 26th 2024

Final Thoughts: The Importance of Comparative Studies in AD

Published: June 6th 2023 | Updated: May 5th 2025

POLL: What Percentage of the Population Has Hidradenitis Suppurativa?

Published: April 29th 2025 | Updated: May 5th 2025

FDA Approves First Gene Therapy for RDEB

$FDA Approves Dupilumab for Adolescents and Adults With H1 Antihistamine-Refractory Chronic Spontaneous Urticaria$

Published: April 18th 2025 | Updated: May 5th 2025

FDA Approves Dupilumab for Adolescents and Adults With H1 Antihistamine-Refractory Chronic Spontaneous Urticaria

Published: April 22nd 2025 | Updated: May 5th 2025

Using Real-World AD Cases to Pick the Right Therapy for Each Patient

Published: April 1st 2025 | Updated: May 5th 2025

Optimizing Vitiligo Care: Key Expert Takeaways